A prognostic biomarker is: a biomarker that provides information on the likely course of the cancer disease in an untreated individual. As most cancer patients are offered some kind of post-surgical treatment (adjuvant treatment), many âprognosticâ studies will nowadays include patients who received systemic anticancer treatment, which may influence the natural course of the disease. Early response to prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia. Using proteomic tools and clinically important leukemia cell lines potential prognostic protein biomarkers has been identified as well as discovered promising regulators of PRED-induced apoptosis. After treatment with PRED, the four cell lines can be separated into resistant (REH) and sensitive (697, Sup-B15, RS4; 11). Apoptotic pathways are frequently altered in both tumor progression and drug resistance; therefore proteins associated with this pathway may have potential as prognostic biomarkers for the disease. Identification of clinical biomarkers that are able to identify patients who are likely to respond to specific chemotherapy will lead to more personalized, effective, and less toxic therapy. Prognostic biomarkers are measured before treatment to indicate long-term outcome for patients and give an estimate of the severity and the likely outcome of diseases. Depending upon the diagnosis of cancer, determining the correct prognosis is essential for patients in order to manage their disease effectively.
Last date updated on July, 2014